未住院的HIV感染患者中耐万古霉素肠球菌定植情况
Vancomycin-resistant enterococcal colonization in nonhospitalized HIV-infected patients.
作者信息
Dhawan V K, Nachum R, Bhat N, Tolbert L, Agrawal M
机构信息
Charles R. Drew University of Medicine and Science, Los Angeles, California, USA.
出版信息
West J Med. 1998 Nov;169(5):276-9.
Abstract
We studied fecal colonization with vancomycin-resistant enterococci (VRE) in 89 HIV-infected nonhospitalized patients ages 24 to 62 years, including 70 (79%) men (including 41 homosexual and 5 bisexual men) and 19 (21%) women. Of the 89 patients, 61 (69%) were black, 25 (28%) Hispanic, and 3 (3%) white; 53 (60%) had history of ongoing or recent antibacterial therapy with trimethoprim/sulfamethoxazole (29), clarithromycin (18), amoxicillin (7), ofloxacin (3), and metronidazole, doxycycline, dicloxacillin, and cephalexin (1 each). VRE were not isolated from any of the patients studied.
摘要
我们对89名年龄在24至62岁的未住院HIV感染患者进行了耐万古霉素肠球菌（VRE）粪便定植情况研究，其中包括70名（79%）男性（包括41名同性恋男性和5名双性恋男性）和19名（21%）女性。89名患者中，61名（69%）为黑人，25名（28%）为西班牙裔，3名（3%）为白人；53名（60%）有正在进行或近期使用甲氧苄啶/磺胺甲恶唑（29例）、克拉霉素（18例）、阿莫西林（7例）、氧氟沙星（3例）以及甲硝唑、强力霉素、双氯西林和头孢氨苄（各1例）进行抗菌治疗的病史。在所研究的患者中均未分离出VRE。
相似文献
1
Vancomycin-resistant enterococcal colonization in nonhospitalized HIV-infected patients.未住院的HIV感染患者中耐万古霉素肠球菌定植情况
West J Med. 1998 Nov;169(5):276-9.
2
Third-generation cephalosporins and vancomycin as risk factors for postoperative vancomycin-resistant enterococcus infection.第三代头孢菌素和万古霉素作为术后耐万古霉素肠球菌感染的危险因素。
Arch Surg. 1998 Dec;133(12):1343-6. doi: 10.1001/archsurg.133.12.1343.
3
Outcome of a screening program for vancomycin-resistant enterococci in a hospital in Victoria.维多利亚一家医院耐万古霉素肠球菌筛查项目的结果
Med J Aust. 1999 Aug 2;171(3):133-6. doi: 10.5694/j.1326-5377.1999.tb123564.x.
4
Vancomycin-resistant-enterococci--colonization of 24 patients on a pediatric oncology unit.耐万古霉素肠球菌——24名儿科肿瘤病房患者的定植情况
Klin Padiatr. 1998 Jul-Aug;210(4):261-3. doi: 10.1055/s-2008-1043889.
5
Treatment options for vancomycin-resistant enterococcal infections.耐万古霉素肠球菌感染的治疗选择。
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.
6
Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia.
Infect Control Hosp Epidemiol. 2000 Dec;21(12):789-91. doi: 10.1086/501735.
7
Vancomycin-resistant Enterococcus faecium colonisations.耐万古霉素屎肠球菌定植
Med J Aust. 1996 Sep 2;165(5):292-3. doi: 10.5694/j.1326-5377.1996.tb124972.x.
8
Vancomycin-resistant enterococcus in end-stage renal disease.终末期肾病中的耐万古霉素肠球菌
Am J Kidney Dis. 1998 Sep;32(3):415-8. doi: 10.1053/ajkd.1998.v32.pm9740157.
9
Antimicrobial resistance profile of Enterococcus species isolated from intestinal tracts of hospitalized patients in Jimma, Ethiopia.从埃塞俄比亚吉马市住院患者肠道中分离出的肠球菌属的抗菌药物耐药性概况。
BMC Res Notes. 2015 Jun 3;8:213. doi: 10.1186/s13104-015-1200-2.
引用本文的文献
1
Prevalence of vancomycin resistant Enterococci and associated risk factors among clients with and without HIV in Northwest Ethiopia: a cross-sectional study.埃塞俄比亚西北部感染和未感染艾滋病毒人群中耐万古霉素肠球菌的患病率及相关危险因素：一项横断面研究
BMC Public Health. 2014 Feb 20;14:185. doi: 10.1186/1471-2458-14-185.
本文引用的文献
1
Vancomycin-resistant enterococci in turkeys and farmers.火鸡和养殖者体内的耐万古霉素肠球菌
N Engl J Med. 1997 Nov 20;337(21):1558-9. doi: 10.1056/NEJM199711203372117.
2
Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community.从动物食品和社区人群粪便样本中分离出的具有vanA介导的高水平糖肽抗性的屎肠球菌菌株。
Microb Drug Resist. 1995 Fall;1(3):265-72. doi: 10.1089/mdr.1995.1.265.
3
Resistance to glycopeptides in enterococci.肠球菌对糖肽类抗生素的耐药性。
Clin Infect Dis. 1997 Apr;24(4):545-54; quiz 555-6. doi: 10.1093/clind/24.4.545.
4
Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States.来自美国医院、社区和动物源的耐万古霉素肠球菌。
Antimicrob Agents Chemother. 1996 Nov;40(11):2605-9. doi: 10.1128/AAC.40.11.2605.
5
Survey of enterococcal susceptibility patterns in Belgium.比利时肠球菌药敏模式调查。
J Clin Microbiol. 1996 Oct;34(10):2572-6. doi: 10.1128/jcm.34.10.2572-2576.1996.
6
Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium.耐万古霉素屎肠球菌或万古霉素敏感屎肠球菌所致菌血症患者的预后差异。
Clin Infect Dis. 1996 Apr;22(4):663-70. doi: 10.1093/clinids/22.4.663.
7
Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci.口服糖肽类药物对人类志愿者粪便菌群的影响：高糖肽耐药肠球菌的筛选
J Infect Dis. 1996 May;173(5):1129-36. doi: 10.1093/infdis/173.5.1129.
8
Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium during its emergence in a city in southern Texas.耐万古霉素屎肠球菌在得克萨斯州南部一个城市出现期间的临床和分子流行病学
Clin Infect Dis. 1995 Nov;21(5):1234-7. doi: 10.1093/clinids/21.5.1234.
9
Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients.定植于住院患者肠道的耐万古霉素肠球菌。
J Clin Microbiol. 1995 Nov;33(11):2842-6. doi: 10.1128/jcm.33.11.2842-2846.1995.
10
Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci.耐万古霉素肠球菌医院感染暴发的流行病学分析及基因分型特征
J Clin Microbiol. 1993 May;31(5):1280-5. doi: 10.1128/jcm.31.5.1280-1285.1993.
Zotero 插件